Praxis Precision Medicines PRAX
$300.43 −$10.47 (-3.37%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $300.43 0.00%
Open$310.07
Prev close$310.90
Day range$298.54 – $314.15
Volume806.2K
Market cap$8.40B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$106.91M-36.4% YoY
Net profit-$94.23M-27.5% YoY
Diluted EPS-$3.23+3.9% YoY
Free cash flow-$82.52M-26.8% YoY
Operating cash flow-$81.74M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-44.8%
Return on assets-42.1%
Return on invested capital-44.8%
Current ratio14.53
Liabilities / assets4.0%
Cash & investments$745.32M
Net cash (debt)$745.32M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $106.91M | $96.90M | $105.86M | $326.20M | $97.04M |
| Selling and Admin Expenses | $42.71M | $27.49M | $27.87M | $59.08M | $19.54M |
| -General & Admin Expense | $42.71M | $27.49M | $27.87M | $59.08M | $19.54M |
| Research & Development | $64.21M | $69.42M | $77.99M | $267.12M | $77.51M |
| Operating Profit | -$106.91M | -$96.90M | -$105.86M | -$326.20M | -$97.04M |
| Other Income (Expense) | $12.68M | $13.18M | $13.30M | $22.93M | $8.13M |
| Other Non-Operating Income (Expenses) | $12.68M | $13.18M | $13.30M | $22.93M | $8.13M |
| Pretax Profit | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Net Profit | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Profit from Continuing Operations | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Net Income to Parent Company | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Net Income to Common Stockholders | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Basic EPS | -$3.23 | -$2.87 | -$3.20 | -$13.48 | -$3.50 |
| Diluted EPS | -$3.23 | -$2.87 | -$3.20 | -$13.48 | -$3.50 |
| Total Revenue as Reported | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.31B | $1.39B | $1.46B | $937.91M | $937.91M |
| Total Current Assets | $762.80M | $771.90M | $797.77M | $610.91M | $610.91M |
| Cash and Cash Equivalents & Short-Term Investments | $745.32M | $758.55M | $786.87M | $599.33M | $599.33M |
| -Cash and Cash Equivalents | $361.85M | $474.76M | $536.33M | $357.33M | $357.33M |
| -Short Term Investments | $383.47M | $283.79M | $250.53M | $242.00M | $242.00M |
| Other Current Assets | $17.48M | $13.35M | $10.91M | $11.58M | $11.58M |
| Total Non-Current Assets | $549.27M | $618.20M | $662.43M | $327.00M | $327.00M |
| Net PPE | $2.58M | $1.49M | $1.49M | $239,000.00 | $239,000.00 |
| -Gross PPE | $2.58M | $1.49M | $1.49M | $1.74M | $1.74M |
| Investments and Advances | $540.70M | $615.29M | $660.94M | $326.76M | $326.76M |
| -Available for Sale Securities | $540.70M | $615.29M | $660.94M | $326.76M | $326.76M |
| Other Non-Current Assets | $6.00M | $643,000.00 | – | – | – |
| Total Liabilities | $52.50M | $49.06M | $50.24M | $59.77M | $59.77M |
| Total Current Liabilities | $52.50M | $49.06M | $50.24M | $59.77M | $59.77M |
| Payables | $15.02M | $23.39M | $31.16M | $24.63M | $24.63M |
| -Accounts Payable | $15.02M | $23.39M | $31.16M | $24.63M | $24.63M |
| Current Accrued Expenses | $29.51M | $20.88M | $14.66M | $16.32M | $16.32M |
| Short-Term Debt and Capital Lease Obligation | $732,000.00 | $1.09M | $1.44M | $110,000.00 | $110,000.00 |
| -Current Capital Lease Obligation | $732,000.00 | $1.09M | $1.44M | $110,000.00 | $110,000.00 |
| Total Non-Current Liabilities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total Equity | $1.26B | $1.34B | $1.41B | $878.14M | $878.14M |
| Stockholders' Equity | $1.26B | $1.34B | $1.41B | $878.14M | $878.14M |
| Capital Stock | $15,000.00 | $15,000.00 | $15,000.00 | $15,000.00 | $15,000.00 |
| -Common Stock | $15,000.00 | $15,000.00 | $15,000.00 | $15,000.00 | $15,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.68B | $2.66B | $2.64B | $2.02B | $2.02B |
| Retained Earnings | -$1.41B | -$1.32B | -$1.23B | -$1.14B | -$1.14B |
| Gains/Losses Not Affecting Retained Earnings | -$5.73M | -$2.67M | -$1.59M | $563,000.00 | $563,000.00 |
| Goodwill and Other Intangible Assets | – | $773,000.00 | – | – | – |
| -Other Intangible Assets | – | $773,000.00 | – | – | – |
| -Accumulated Depreciation | – | – | – | -$1.50M | -$1.50M |
| Long Term Debt and Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
| -Long Term Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$81.74M | -$77.54M | -$86.15M | -$249.07M | -$76.33M |
| Net cash flow from continuing operations | -$81.74M | -$77.54M | -$86.15M | -$249.07M | -$76.33M |
| Net Income from Continuing Operations | -$94.23M | -$83.72M | -$92.56M | -$303.27M | -$88.91M |
| Depreciation & Depletion & Amortization | $33,000.00 | $33,000.00 | $39,000.00 | $140,000.00 | $28,000.00 |
| Other Non-Cash Items | $327,000.00 | $319,000.00 | $197,000.00 | $1.03M | $264,000.00 |
| Change in Working Capital | -$1.93M | -$4.79M | -$10.28M | $22.68M | $3.03M |
| -Change in Prepaid Assets | -$4.12M | -$2.86M | $672,000.00 | $640,000.00 | -$4.89M |
| -Change in Payables and Accrued Expense | $3.91M | -$943,000.00 | -$10.86M | $23.30M | $8.23M |
| -Change in Other Current Liabilities | -$355,000.00 | -$348,000.00 | -$101,000.00 | -$1.26M | -$326,000.00 |
| -Change In Other Working Capital | -$1.35M | – | – | – | – |
| Net cash flow from investing | -$32.10M | $10.98M | -$344.28M | -$311.15M | -$328.39M |
| Net Cash Flow from Continuing Investing Activities | -$32.10M | $10.98M | -$344.28M | -$311.15M | -$328.39M |
| Net PPE Purchase and Sale | -$1.55M | -$245,000.00 | -$62,000.00 | -$56,000.00 | $0.00 |
| Net Investment Purchase and Sale | -$27.32M | $12.00M | -$344.21M | -$311.09M | -$328.39M |
| Financing Cash Flow | $929,000.00 | $4.57M | $609.43M | $702.17M | $612.52M |
| Net Cash Flow from Continuing Financing Activities | $929,000.00 | $4.57M | $609.43M | $702.17M | $612.52M |
| Net Common Stock Issuance | $0.00 | $0.00 | $621.24M | $690.99M | $601.73M |
| Proceeds from Stock Option Exercised | $1.42M | $4.88M | $1.12M | $13.27M | $11.61M |
| Net Other Financing Charges | -$493,000.00 | -$310,000.00 | -$12.92M | -$2.09M | -$819,000.00 |
| Ending Cash Balance | $361.85M | $474.76M | $536.75M | $357.75M | $357.75M |
| Net Change in Cash | -$112.91M | -$61.99M | $179.00M | $141.96M | $207.80M |
| Beginning Cash Balance | $474.76M | $536.75M | $357.75M | $215.79M | $149.94M |
| Free Cash Flow | -$82.52M | -$78.56M | -$86.21M | -$249.12M | -$76.33M |
No comments yet — be the first to weigh in on PRAX.
Sign in to join the discussion.